Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
NCT ID: NCT00052208
Last Updated: 2020-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
158 participants
INTERVENTIONAL
2002-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To identify the maximum tolerated dose of ZD 1839 (gefitinib) when given concurrently with cranial radiotherapy.
II. To determine if ZD 1839, given orally on a daily basis starting at the time of conventional radiation therapy (RT), may improve the overall survival of adults with newly-diagnosed supratentorial glioblastoma multiforme, compared with historical controls, stratifying by epidermal growth factor receptor (EGFR) status.
III. To determine, in a multi-institutional setting, the feasibility and toxicity of prescribing ZD 1839.
SECONDARY OBJECTIVES:
I. Whether ZD 1839 also improves progression-free survival in these patients.
OUTLINE: This is a phase I, dose-escalation study of gefitinib followed by a phase II study.
Patients receive gefitinib orally (PO) once daily (QD) for 7 weeks. Beginning 1 week after initiation of gefitinib, patients undergo radiation therapy QD 5 days a week for 6 weeks. Treatment with gefitinib continues for up to 18 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 4 months for 1 year, every 6 months for 2 years, and annually thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (gefitinib, radiation therapy)
Patients receive gefitinib PO QD for 7 weeks. Beginning 1 week after initiation of gefitinib, patients undergo radiation therapy QD 5 days a week for 6 weeks. Treatment with gefitinib continues for up to 18 months in the absence of disease progression or unacceptable toxicity.
gefitinib
Given PO
radiation therapy
Undergo radiation therapy
laboratory biomarker analysis
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gefitinib
Given PO
radiation therapy
Undergo radiation therapy
laboratory biomarker analysis
Correlative studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis must be made by surgical biopsy or excision
* The tumor must be supratentorial in location
* The patient must have recovered from the effects of surgery, post-operative infection, or other complications before study entry
* Radiotherapy must begin =\< five weeks after surgery, and Iressa (gefitinib) must begin one week prior to radiotherapy
* Patients must have an estimated survival of at least 8 weeks
* Zubrod performance status of 0-1
* A diagnostic contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) scan must be performed preoperatively and postoperatively prior to the initiation of radiotherapy; preoperative and postoperative scans must be the same type
* Patients diagnosed only by stereotactic biopsy do not require the postoperative scan
* Patients unable to undergo magnetic resonance (MR) imaging because of non-compatible devices can be enrolled, provided pre and postoperative CT scans are obtained and are of sufficient quality
* Hemoglobin \>= 10 grams
* Absolute neutrophil count \>= 1500 (ANC) per mm\^3
* Platelets \>= 100,000 per mm\^3
* Blood urea nitrogen (BUN) =\< 25 mg
* Creatinine =\< 1.5 mg
* Bilirubin =\< 2.0 mg
* Serum glutamate pyruvate transaminase (SGPT) or serum glutamic oxaloacetic transaminase (SGOT) =\< 2 x normal range
* Patients must consent to submission of their tissue/serum
* The patient must sign a study-specific informed consent prior to study entry; if the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the responsible family member
Exclusion Criteria
* Metastases detected below the tentorium or beyond the cranial vault
* Major medical illnesses or psychiatric impairments which, in the investigator's opinion, will prevent administration or completion of protocol therapy
* Previous radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields
* Active connective tissue disorders, such as lupus or scleroderma which, in the opinion of the treating physician, may put the patient at high risk for radiation toxicity
* Previous malignancies, except for non-melanomatous skin cancers and carcinoma in situ of the uterine cervix or bladder, unless disease-free for \>= 3 years
* Prior chemotherapy or radiosensitizers for cancers of the head and neck region
* Patients with known acquired immune deficiency (AIDS); patients with AIDS require complex therapeutic regimens; the pharmacokinetic interactions of these regimens with ZD 1839 are unknown and therefore, pose a safety risk related to excess toxicity or interference with anti-viral effectiveness
* Patients with known multiple sclerosis, as these patients may have decreased tolerance for radiation therapy to the brain
* Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to study drug
* Patients treated on any other clinical protocols within 30 days prior to study entry or during participation in the study
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NRG Oncology
OTHER
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arnab Chakravarti
Role: PRINCIPAL_INVESTIGATOR
Radiation Therapy Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Radiation Therapy Oncology Group
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RTOG-0211
Identifier Type: -
Identifier Source: secondary_id
CDR0000069330
Identifier Type: -
Identifier Source: secondary_id
RTOG-BR-0211
Identifier Type: -
Identifier Source: secondary_id
NCI-2013-00849
Identifier Type: -
Identifier Source: org_study_id